Table 2.
Univariate analysis of breast cancer SLN metastasis in primary and validation cohorts.
| Variable | Primary cohort (N=902) | P-Value | Validation cohort (N=50) | P-Value | ||
|---|---|---|---|---|---|---|
| SLN metastasis(N=372) | SLN non-metastatic(N=530) | SLN metastasis(N=22) | SLN non-metastatic(N=28) | |||
| shape | <0.001 | 0.277 | ||||
| oval | 0 | 0 | 0 | 0 | ||
| round | 4 (1.1%) | 33 (6.2%) | 5 (22.7%) | 3 (10.7%) | ||
| Irregular | 368 (98.9%) | 497 (93.8%) | 17 (77.3%) | 25 (89.3%) | ||
| orientation | <0.001 | 0.153 | ||||
| parallel | 201 (54.0%) | 368 (69.4%) | 9 (40.9%) | 18 (64.3%) | ||
| not parallel | 171 (46.0%) | 162 (30.6%) | 13 (59.1%) | 10 (35.7%) | ||
| margin | <0.001 | 0.014 | ||||
| circumscribed | 5 (1.3%) | 20 (3.8%) | 0 | 0 | ||
| indistinct | 24 (6.5%) | 117 (22.1%) | 0 | 4 (14.3%) | ||
| angular | 56 (15.1%) | 266 (50.2%) | 2 (9.1%) | 6 (21.4%) | ||
| micro lobulated | 75 (20.2%) | 93 (17.5%) | 4 (18.2%) | 10 (35.7%) | ||
| spiculated | 212 (56.9%) | 34 (6.4%) | 16 (72.7%) | 8 (28.6%) | ||
| echo pattern | 0.613 | 0.262 | ||||
| anechoic | 0 | 0 | 0 | 0 | ||
| hyperechoic | 0 | 0 | 0 | 0 | ||
| isoechoic | 76 (20.4%) | 111 (20.9%) | 3 (13.6%) | 9 (32.1%) | ||
| complex cystic and solid | 8 (2.2%) | 17 (3.2%) | 2 (9.1%) | 1 (3.6%) | ||
| hypoechoic | 288 (77.4%) | 402 (75.9%) | 17 (77.3%) | 18 (64.3%) | ||
| posterior features | <0.001 | 0.045 | ||||
| enhancement | 59 (15.9%) | 144 (27.2%) | 0 | 6 (21.4%) | ||
| no posterior features | 69 (18.5%) | 164 (30.9%) | 8 (36.4%) | 11 (39.3%) | ||
| shadowing | 244 (65.6%) | 222 (41.9%) | 14 (63.6%) | 11 (39.3%) | ||
| calcifications | <0.001 | 0.004 | ||||
| rim calcification | 10 (2.7%) | 7 (1.3%) | 0 | 1 (3.6%) | ||
| no calcification | 75 (20.2%) | 275 (51.9%) | 1 (4.5%) | 12 (42.9%) | ||
| macrocalcification | 66 (17.7%) | 231 (43.6%) | 8 (36.4%) | 10 (35.7%) | ||
| microcalcification | 221 (59.4%) | 17 (3.2%) | 13 (59.1%) | 5 (17.8%) | ||
| architectural distortion | <0.001 | 0.001 | ||||
| no | 23 (6.2%) | 319 (60.2%) | 4 (18.2%) | 19 (67.9%) | ||
| yes | 349 (93.8%) | 211 (39.8%) | 18 (81.8%) | 9 (32.1%) | ||
| suspicious lymph node | <0.001 | 0.047 | ||||
| no | 110 (29.6%) | 487 (91.9%) | 6 (27.3%) | 16 (57.1%) | ||
| yes | 262 (70.4%) | 43 (8.1%) | 16 (72.7%) | 12 (42.9%) | ||
| duct changes | 0.032 | 0.393 | ||||
| no | 159 (42.7%) | 264 (49.8%) | 10 (45.5%) | 17 (60.7%) | ||
| yes | 213 (57.3%) | 266 (50.2%) | 12 (54.5%) | 11 (39.3%) | ||
| hyperechoic halo | 0.855 | 1.000 | ||||
| no | 247 (66.4%) | 355 (67.0%) | 16 (72.7%) | 20 (71.4%) | ||
| yes | 125 (33.6%) | 175 (33.0%) | 6 (27.3%) | 8 (28.6%) | ||
SLN, sentinel lymph node.